The siRNA-based therapy specifically targets photoreceptor cells in the eye, halting disease progression for six months to a year.

A siRNA therapeutic for dermatological diseases developed at UMass Chan Medical School has entered the clinical trial phase.

UMass Chan Medical School has licensed siRNA chemistries developed by Julia Alterman, PhD, to Aldena Therapeutics for clinical development for dermatological diseases.

Two research teams from UMass Medical School have been selected by STAT News to compete among 64 contestants in the 2020 STAT Madness, a bracket-style competition in which members of the public will vote for the best biomedical research from 2019.

Neil Aronin, MD, led an afternoon of presentations detailing advances made by scientists at UMass Medical School in the quest to find a treatment for Huntington’s disease. CHDI Foundation President Robi Blumenstein accepted a plaque in recognition of the foundation’s $13 million in support of Huntington’s research at the medical school.

At the annual student achievement awards ceremony for the Graduate School of Biomedical Sciences, Dean Mary Ellen Lane encouraged students to seek happiness through love, meaningful work and hope for the future, following in the steps of Joseph Addison, an English playwright and politician.